


a compound having the following formula:



or a prodrug derivative thereof, wherein G_1 is selected from the group consisting of $(\text{C}_1\text{-C}_6)$ alkyl, $(\text{C}_1\text{-C}_6)$ alkenyl, aryl group or a heteroaryl group, wherein the aryl or heteroaryl is a ring having 5, 6 or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein G_2 is a group having a neutral or a net charge, selected from the following: $-\text{CN}(\text{R}_1\text{R}_2\text{R}_3)$, $-\text{CN}(\text{R}_1\text{R}_2)$, $-\text{N}(\text{R}_1\text{R}_2\text{R}_3)$, $-\text{N}(\text{R}_1\text{R}_2)$, or a heteroaryl group, wherein the heteroaryl is a ring having 5, 6 or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein R_1 , R_2 and R_3 independent of one another are selected from the group consisting of $-\text{H}$, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, or other linear alkyl groups such as propyl, butyl, or pentyl, wherein G_3 and G_4 independent of one another are selected from the group consisting of N, S, O, $(\text{C}_1\text{-C}_6)$ alkyl, and $(\text{C}_1\text{-C}_6)$ alkenyl, wherein X is a $(\text{C}_1\text{-C}_{12})$ alkyl and wherein Z is present as a charged species when G_2 has a net charge, the charge of Z depends on the charge of G_2 , Z is absent when G_2 is neutral in charge; and

C1
cont.
a pharmaceutically acceptable carrier.

C2
2. (Thrice Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of N-ethyl-N'-(3-dimethylaminopropyl) urea or a salt thereof in combination with a pharmaceutically acceptable solid carrier.

C3
72. (Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of N-ethyl-N'-(3-dimethylaminopropyl) urea or a salt thereof in combination with a pharmaceutically acceptable sterile liquid carrier.

C4
74. (Amended) A pharmaceutical composition comprising an aerosol form of a pharmaceutically effective amount of N-ethyl-N'-(3-dimethylaminopropyl) urea or a salt thereof.

✓
Please add the following new claim:

C5
75. (New) The pharmaceutical composition of claim 72 wherein the pharmaceutically acceptable sterile liquid carrier is isotonic.

REMARKS

Applicants appreciate the Examiner's review of the present application and respectfully requests reconsideration in view of the preceding amendments and the following remarks. Claims 1-74 are pending in the application. Claims 1 and 3-71 are withdrawn from consideration based on Applicants' election in response to the Examiner's restriction requirement. Claim 73 has been cancelled; claim 75 has been added; claims 1, 2, 72 and 74 have been amended in the present amendment. Support for the amended and newly added claims can be found throughout the specification. More specifically, support for the recitation of "neutral" form of compound in claim